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Vitamin D dependent rickets type I
Vitamin D is present in two forms, ergocalciferol (vitamin D2) produced 
by plants and cholecalciferol (vitamin D3) produced by animal tissues 
or by the action of ultraviolet light on 7-dehydrocholesterol in human 
skin. Both forms of vitamin D are biologically inactive pro-hormones 
that must undergo sequential hydroxylations in the liver and the 
kidney before they can bind to and activate the vitamin D receptor. 
The hormonally active form of vitamin D, 1,25-dihydroxyvitamin D3 
[1,25(OH)2D], plays an essential role in calcium and phosphate met-
abolism, bone growth, and cellular differentiation. Renal synthesis of 
1,25(OH)2D from its endogenous precursor, 25-hydroxyvitamin D 
(25OHD), is the rate-limiting and is catalyzed by the 1α-hydroxylase. 
Vitamin D dependent rickets type I (VDDR-I), also referred to as 
vitamin D 1α-hydroxylase deficiency or pseudovitamin D deficiency 
rickets, is an autosomal recessive disorder characterized clinically by 
hypotonia, muscle weakness, growth failure, hypocalcemic seizures 
in early infancy, and radiographic findings of rickets. Characteristic 
laboratory features are hypocalcemia, increased serum concentrations 
of parathyroid hormone (PTH), and low or undetectable serum con-
centrations of 1,25(OH)2D despite normal or increased concentrations 
of 25OHD. Recent advances have showed in the cloning of the human 
1α-hydroxylase and revealed mutations in its gene that cause VDDR-I. 
This review presents the biology of vitamin D, and 1α-hydroxylase 
mutations with clinical findings.
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catalyzed by the mitochondrial cytochrome P450 enzyme, 25OHD­
1α ­hydroxylase (1α ­hydroxylase, P450c1α )
1, 2). Vitamin D dependent 
rickets type I (VDDR­I), also referred to as vitamin D 1α ­hydroxylase 
deficiency or pseudovitamin D deficiency rickets, is an autosomal 
recessive disorder caused by mutations of the 1α ­hydroxylase gene
3­
5). Characteristic laboratory features are hypocalcemia, increased 
serum concentrations of parathyroid hormone (PTH), and low or 
undetectable serum concentrations of 1,25(OH)2D despite normal 
Introduction
1,25­dihydroxyvitamin D3 [1,25(OH)2D] is one of the principle 
hormonal regulators of calcium and phosphorus metabolism in the 
body and is critically important for normal growth and mineralization 
of bone. Renal synthesis of 1,25(OH)2D from its endogenous 
precursor, 25­hydroxyvitamin D (25OHD), is the rate­limiting, 
hormonally regulated step in the bioactivation of vitamin D and is 52      CJ Kim • Vitamin D dependent rickets type I
or increased concentrations of 25OHD. Physiological doses of 1α
(OH) vitamin D3 (1α ­OHD) or 1,25(OH)2D3 induce remission of 
the clinical and laboratory abnormalities
3). This review presents the 
biology of vitamin D, and 1α ­hydroxylase mutations with clinical 
findings.
Biosynthesis of vitamin D
Vitamin D exists as either ergocalciferol (vitamin D2) produced 
by plants, or cholecalciferol (vitamin D3) produced by animal 
tissues and by the action of ultraviolet radiation (290­310 nm) on 
7­dehydrochoesterol in human skin
6, 7). Vitamin D2 differs from D3 
only in having a 22, 23 double bond and having an additional methyl 
group attached to carbon 24. Both forms of vitamin D are biologically 
inactive pro­hormones that must undergo successive hydroxylations 
at carbons 25 and 1 before they can bind to and activate the vitamin 
D receptor. The 25­hydroxylation of vitamin D occurs primarily in 
the liver, catalyzed by the mitochondrial cytochrome P450 enzyme, 
P450c25. The activity of the hepatic 25­hydroxylase is not under 
tight physiologic regulation, and thus the circulating concentration 
of 25OHD is determined primarily by one’s dietary intake of 
vitamin D and amount of sunlight exposure. Although 25OHD is 
the most abundant form of vitamin D in the blood, it has minimal 
capacity to bind to the vitamin D receptor and elicit a biological 
response
8). The active form of vitamin D, 1,25(OH)2D, is produced 
in the proximal renal tubule by the 1α ­hydroxylation of 25OHD. 
The circulating concentration of 1,25(OH)2D primarily reflects its 
synthesis in the kidney. The 1α ­hydroxylase is the rate­limiting step 
in the bioactivation of vitamin D, and enzyme activity in the kidney 
is tightly regulated by PTH, calcium, phosphorus, and 1,25(OH)2D 
itself
 9, 10). 
Vitamin D 1α-hydroxylase 
The human 1α ­hydroxylase gene has been cloned and mapped 
to the chromosome 12q13.1­q13.3 at the same locus
11­14) as the 
autosomal recessive VDDR­I. It is approximately 5 Kb and is 
composed of nine exons
13). Furthermore, several laboratories have 
characterized mutations in the 1α ­hydroxylase gene in patients with 
VDDR­I
14­23). VDDR­I is characterized by failure to thrive, muscle 
weakness, hypocalcemia, secondary hyperparathyroidism, and the 
bony changes of rickets
3). The hallmarks of the diseases are greatly 
reduced serum concentration of 1,25(OH)2D despite normal or 
increased concentrations of 25OHD, and the reversal of clinical and 
laboratory abnormalities by administration of physiologic amounts 
of 1,25(OH)2D
3­5). To date, a total of 36 mutations in the 1α
­hydroxylase gene have been identified in patients with VDDR­I
22). 
All but one of the frameshift and premature translation­arrest 
mutations described eliminate the heme­binding site of P450c1α , 
hence the resultant protein cannot have 1α ­hydroxylase activity. 
Two mutations described in 1α ­hydroxylase gene are relatively more 
common than the others. Deletion of guanine 958 (958delG), as 
numbered from the gene’s transcriptional start site
13), was found on 20 
French Canadian alleles
16, 17); microsatellite haplotype analysis showed 
that these arose from a single founder
17, 24). A 7 nucleotide insertion in 
exon 8 was found in 14 affected alleles
16­18); these arose from various 
ethnic groups with different microsatellite haplotypes
17).
So far, 5 Korean patients with VDDR­I have been studied 
at a molecular genetic level and 3 distinct mutations have been 
identified
22). The clinical data for these patients were summarized in 
Table 1. Patient 1 presented with bowing of the legs at 12 months of 
age. He had a prominent forehead with craniotabes, rachitic rosary, 
and genu varus. Laboratory data revealed hypocalcemia, high serum 
alkaline phosphatase and PTH concentrations, and radiographic 
features of rickets. Treatment with 1a­OHD resulted in improvement 
of clinical, radiographic, and laboratory abnormalities. Patient 2 
developed recurrent seizures at 5 months of age. At 15 months of 
age she was found to have kyphosis, prominent rachitic rosary, a 
widely open anterior fontanel, varus deformity of the elbow, and x­ray 
findings of severe rickets with fractures of both fibulae. Laboratory 
data revealed hypocalcemia, high serum alkaline phosphatase and 
PTH concentrations, and low 1,25(OH)2D concentration. She 
Table 1. Clinical and Biochemical Features in Four Patients with Vitamin D Dependent Rickets Type I
Patient  
no.   
Age at diagnosis                         
(months)            
Presentation   
Serum Ca      
(mg/dL)  
Serum P     
(mg/dL)          
Serum ALP  
(IU/L)      
Serum PTH  
(pg/mL)  
Serum 25OHD  
(ng/mL)  
Serum 1,25-(OH)2D
(pg/mL)
1 12     bowed legs       6.0      3.8      1,050        560      336       <7 
2  5     rachitic rosary     6.4      4.0      2,043       1,320      27        9.2
3         7     seizure           5.2      6.2       665       750       38        <5
4        14     femur fracture     7.3      5.0      1,437        N/A      16        <5
5         5     rachitic rosary     5.9      3.6      1,326        750      77       <4
Abbreviations; ALP, alkaline phosphatase; N/A, not available.Korean J Pediatr 2011;54(2):51-54 • DOI: 10.3345/kjp.2011.54.2.51    53
was successfully treated with 1a­OHD. Patient 3 presented with a 
hypocalcemic seizure at 5 months of age. At 25 months of age he was 
found to have a prominent forehead, rachitic rosary, and bowing of 
the legs. Laboratory evaluation showed hypocalcemia, high serum 
alkaline phosphatase activity, and low 1,25(OH)2D concentration. 
Radiographs revealed features of severe rickets. She responded 
well to 1a­OHD. Patient 4 presented with a femur fracture after 
minor trauma at the age of 14 months. He had hypocalcemia, high 
alkaline phosphatase activity, low 1,25(OH)2D concentration, and 
rachitic changes on x­ray. Administration of 1a­OHD resulted in 
normalization of clinical, radiographic, and laboratory abnormalities. 
Patient 5 presented with a hypocalcemic seizure at 5 months of 
age and was treated with calcium and vitamin D. At 17 months 
of age he was noted to have rachitic rosary, prominent forehead, 
and enlargement of wrists and ankles. Laboratory data revealed 
hypocalcemia, high serum alkaline phosphatase concentration, and 
rachitic changes on x­ray. Serum concentration of 25OHD was above 
the normal range whereas that of 1, 25­(OH)2D was not detectable. 
He responded well to administration of 1α ­OHD.
On molecular genetic studies, patient 1 was homozygous for a 
splice site mutation, substitution of an adenine for a guanine in the 
first nucleotide of intron 3 (IVS3+1 G>A). This mutation disrupts 
the splice donor site resulting in retention of intron 3. The retained 
intron would create a frameshift after codon 196 and a translational 
termination signal 63 bp downstream from the end of exon 3, 
resulting in a severely truncated protein that cannot have enzymatic 
activity. Patient 2 was homozygous for a 7 nucleotide insertion in 
exon 8; this mutation alters the reading frame downstream of codon 
442 and creates a premature TGA stop signal at codon 446
17). 
Patients 3 and 4 were compound heterozygous for the two mutations 
detected in patients 1 and 2. Patient 5 was compound heterozygous 
for the mutation detected in patient 1, IVS3+1 G>A, and for a novel 
nonsense mutation, 2561G>A in exon 6 that creates a premature 
TAG stop signal at codon 328. Analysis of the family members 
showed that the asymptomatic parents and the brother of patient 
1 were heterozygous for the IVS3+1 G>A mutation. The mother 
and the brother of patient 2 were heterozygous for the 7 nucleotide 
insertion in exon 8; DNA from the father was not available for study. 
The mother of patient 3 was heterozygous for IVS3+1 G>A, and 
the father and sister were heterozygous for the 7 nucleotide insertion 
in exon 8. The mother of the patient 4 was heterozygous for the 7 
nucleotide insertion in exon 8; the father was not studied. The mother 
and brother of patient 5 were heterozygous for the IVS3+1 G>A, and 
the father was heterozygous for the 2651G>A mutation in exon 6.
There are two common mutation sites in 5 Korean patients with 
VDDR­I (Table 2). The splice site mutation, IVS3+1 G>A, occurred in 
5 of 10 alleles. Guanine to adenine substitution in the first nucleotide 
of an intron is a common mutation in many genes and usually results 
in skipping of the 5'­exon or activation of potential splice sites
25). 
However, in short introns, retention of the intron may also occur as 
has been demonstrated for IVS3+1 G>A in the 1α ­hydroxylase
19, 25). 
The retention of intron 3 causes altered translation and a premature 
stop codon 63 bp downstream from the end of exon 3. The resulting 
truncated 1α ­hydroxylase would have only 197 of 508 amino acids, 
would lack the heme­binding domain, and hence would have no 
enzyme activity. The 1α­hydroxylase gene contains the normally 
duplicated sequence 5'­CCCACCC CCCACCC­3' in exon 8, 
which encodes residues 438­442 (Pro­Thr­Pro­His­Pro). Korean 
patients showed triplication rather than duplication of this 7 nucleotide 
sequence on 4 alleles. This 7 nucleotide insertion alters the reading 
frame downstream of codon 442 and creates a premature TGA 
stop signal at codon 446; this is upstream from the heme­binding 
domain, hence the resulting truncated protein is devoid of activity
17). 
Wang et al.
17) previously reported that six families of widely divergent 
ethnic backgrounds (Filipino, Polish, Chinese, Caucasian American, 
African American, and Hispanic) carried this 7 nucleotide insertion 
in association with four different microsatellite haplotypes. Thus, 
the ethnic and haplotype diversity associated with the 7 nucleotide 
insertion suggests that it has risen by several independent de novo 
events, probably as the result of a slipped­strand mispairing mechanism 
during meiosis
26). Kitanaka et al.
19) found 10 different 1α ­hydroxylase 
gene mutations in 20 Japanese alleles, suggesting that there is no 
founder effect in that ethnic group. By contrast, Korean patients 
revealed only three different mutations in ten alleles, suggesting that 
in Korean ethnic group, the genetic defect in the 1α ­hydroxylase gene 
is more homogeneous.
Conclusion 
The main hormonal regulator of bone mineralization is vitamin D. 
Dietary deficiency of vitamin D and genetic disorders of vitamin D 
biosynthesis and action can cause rickets. The patients with VDDR­I 
Table 2. 1α-hydroxylase Gene Mutations in 5 Korean Patients (10 
alleles) with Vitamin D Dependent Rickets Type I
Alleles Nucleotide Change* Amino Acid Change Location
5 IVS3+1 G>A (1796G>A) frameshift after 196E Intron 3
4 3398-3406insCCCACCC frameshift after 442P Exon 8
1 2561G>A W328X Exon 6
*Nucleotide numbers refer to genomic DNA and are numbered from the 
transcription start site 13).  The reference sequence is available on the NCBI, 
Entrez, Nucleotide database: http://www.ncbi.nlm.nih.gov/Entrez; accession 
number AF 027152.54      CJ Kim • Vitamin D dependent rickets type I
have mutations in the gene encoding renal 1α ­hydroxylase. A total of 
36 mutations in the 1α ­hydroxylase gene have been identified. Two 
mutations (958delG, 7 nucleotide insertion in exon 8) described in 
1α ­hydroxylase gene are relatively more common than the others. 
Until now, 5 Korean patients with VDDR­I have been studied and 
3 distinct mutations have been identified. There are two common 
mutation sites; IVS3+1 G>A and 7 nucleotide insertion in exon 8. 
Japanese patients with VDDR­I revealed 10 different 1α ­hydroxylase 
gene mutations in 20 alleles. By contrast, Korean patients showed 
only three different mutations in ten alleles, suggesting that the 
genetic defect in the 1α ­hydroxylase gene is more homogeneous in 
Korean ethnic group.
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